To explore this, AAC1 adenoma cells (normally express ∼85% of their VEGF as VEGF165b) were treated with either an anti-VEGF165b-specific antibody (R&D Systems, cat no. MAB3045) or bevacizumab at increasing doses for 48 h. Here, VEGFA is linked to adenoma.